Literature DB >> 26097608

Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease: a preliminary case-control study.

Pengbo Wu1, Yonglong Hua2, Shiyun Tan1, Ming Li1, Yongxiang Shu1, Guo Fang1.   

Abstract

NAFLD is a complex disease characterized by inflammation and insulin resistance which is determined by an interaction of genetics and environmental factors. MMP gene has been implicated in relation to inflammation and insulin resistance. The preliminary case-control study aimed to investigate the association between Matrix metalloproteinase (MMP)-9-1562C/T (rs3918242), MMP-2-1306C/T (rs243865) and risk of NAFLD and to further evaluate the interactions of central obesity with rs3918242 and rs243865. Two variants, rs3918242 and rs243865, were genotyped by polymerase chain reaction -restriction fragment length polymorphism. Gene-environment interactions on risk of NAFLD was preliminarily investigated by generalized multifactor dimensionality reduction (GMDR) and further confirmed by unconditional logistic regression methods. After adjusting for covariates, increased risk of NAFLD were observed in subjects carrying TT/CT genotypes in rs3918242 ((Adjust)OR=1.64, 95% CI: 1.24, 2.11, P=0.006). However, decreased risk of non-alcoholic fat liver disease was found when MMP-2 rs243865 (TT/CT) genotype carriers compared with CC carrier ((Adjust)OR=0.65, 95% CI: 0.47, 0.72, P=0.000).Interactions of central obesity with rs3918242 was preliminarily found by GMDR, with a maximum prediction accuracy (67.61%) and a maximum Cross-validation Consistency (10/10).The unconditional logistic regression method indicated central obesity-positive subject with genotype TT/CT had 4.54 times risk of NAFLD compared to central obesity-negative subjects with genotype CC (OR(add)(a)=4.54, 95% CI: 2.81, 7.21, P(add)(a)=0.000), which further confirmed the interactions. The results indicate that both rs3918242 and rs243865 is associated with risk of NAFLD. Furthermore, rs3918242 and central obesity have synergistic effects on risk of NAFLD.

Entities:  

Keywords:  Interactions; central obesity; matrix metalloproteinase; non-alcoholic fat liver disease; polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26097608      PMCID: PMC4466995     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  [Diagnostic criteria of nonalcoholic fatty liver disease].

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-02

2.  A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence.

Authors:  Xiang-Yang Lou; Guo-Bo Chen; Lei Yan; Jennie Z Ma; Jun Zhu; Robert C Elston; Ming D Li
Journal:  Am J Hum Genet       Date:  2007-04-25       Impact factor: 11.025

Review 3.  Matrix metalloproteinases as modulators of inflammation.

Authors:  Anne M Manicone; John K McGuire
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

4.  Obesity-related non-alcoholic fatty liver disease (NAFLD): A multifactorial process.

Authors:  Ángel Carazo; Javier Salmerón
Journal:  Rev Esp Enferm Dig       Date:  2014-12       Impact factor: 2.086

Review 5.  Current concepts in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Nahum Méndez-Sánchez; Marco Arrese; Daniel Zamora-Valdés; Misael Uribe
Journal:  Liver Int       Date:  2007-05       Impact factor: 5.828

6.  Matrix metalloproteinases contribute to insulin insufficiency in Zucker diabetic fatty rats.

Authors:  Yun-Ping Zhou; Azadeh Madjidi; Maria E Wilson; David A Nothhelfer; John H Johnson; John F Palma; Anthony Schweitzer; Charles Burant; John E Blume; Jeffrey D Johnson
Journal:  Diabetes       Date:  2005-09       Impact factor: 9.461

Review 7.  Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.

Authors:  Anna Wieckowska; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

8.  Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels.

Authors:  Ling-Ling Jiang; Lin Li; Xiao-Fei Hong; You-Ming Li; Bing-Ling Zhang
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 2.566

Review 9.  The adipocyte as an endocrine cell.

Authors:  Nils Halberg; Ingrid Wernstedt-Asterholm; Philipp E Scherer
Journal:  Endocrinol Metab Clin North Am       Date:  2008-09       Impact factor: 4.741

10.  Prevalence of fatty liver disease and its risk factors in the population of South China.

Authors:  Yong-Jian Zhou; Yu-Yuan Li; Yu-Qiang Nie; Jin-Xiang Ma; Lun-Gen Lu; Sheng-Li Shi; Min-Hu Chen; Pin-Jin Hu
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

View more
  5 in total

1.  What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?

Authors:  Mariana V Machado; Sara Policarpo; J Coutinho; Sofia Carvalhana; Jorge Leitão; Armando Carvalho; Ana P Silva; Francisco Velasco; Isabel Medeiros; Ana Catarina Alves; Mafalda Bourbon; Helena Cortez-Pinto
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

2.  Anti-Inflammatory and Antioxidant Properties of Black Mulberry (Morus nigra L.) in a Model of LPS-Induced Sepsis.

Authors:  Karine de Pádua Lúcio; Ana Carolina Silveira Rabelo; Carolina Morais Araújo; Geraldo Célio Brandão; Gustavo Henrique Bianco de Souza; Regislainy Gomes da Silva; Débora Maria Soares de Souza; André Talvani; Frank Silva Bezerra; Allan Jefferson Cruz Calsavara; Daniela Caldeira Costa
Journal:  Oxid Med Cell Longev       Date:  2018-11-07       Impact factor: 6.543

3.  The relationship between MMP9 and ADRA2A gene polymorphisms and mothers-newborns' nutritional status: an exploratory path model (STROBE compliant article).

Authors:  Cristina Oana Mărginean; Claudiu Mărginean; Claudia Bănescu; Lorena Elena Meliţ; Florin Tripon; Mihaela Iancu
Journal:  Pediatr Res       Date:  2019-02-21       Impact factor: 3.756

4.  FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.

Authors:  Audrey Coilly; Christophe Desterke; Catherine Guettier; Didier Samuel; Franck Chiappini
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

5.  24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.

Authors:  Laura Pérez-Is; Julio Collazos; Belén de la Fuente; Luis Morano; Maria Rivas-Carmenado; Manuel Rodriguez; Adolfo Romero-Favela; Galilea de Jesús Fonseca-González; Santiago Melón; Eulalia Valle-Garay; Víctor Asensi
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.